Dr. Adedayo Joseph, an oncologist at Lagos University Teaching Hospital, is leading a major multi-country trial called HYPOAfrica in Nigeria. The trial tests hypofractionated radiotherapy, a treatment that delivers radiation in fewer but higher doses. Researchers want to know if this treatment is safe and effective for African patients, especially in hospitals with limited equipment and staff shortages. Patient recruitment for the study has now finished.
Nigeria has a population of around 238 million people, yet it had no dedicated paediatric radiation oncology programme until Joseph founded one in 2020. Since equivalent training did not exist in Sub-Saharan Africa, she completed her training in Germany and the United States before forming a specialized team at her hospital.
In addition to her hospital work, Joseph leads the Dorcas Cancer Foundation, which assists families with transportation and follow-up care. This initiative reduced the average time from diagnosis to treatment from about 200 days to just over 50 days. Additionally, treatment abandonment dropped from over 50 percent to under 10 percent. Joseph hopes these improvements will help establish better cancer care across Africa.
Difficult words
- trial — a test of the quality or effectiveness of something
- dose — a measured amount of medicine given at one timedoses
- shortage — a state where there is not enough of somethingshortages
- recruitment — the process of finding people to join a study
- equivalent — having the same value, purpose, or importance as something
- initiative — a new plan or action to solve a problem
- abandonment — the act of stopping or leaving something before completion
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is it important to test medical treatments in different countries and settings?
- How can practical support, like transportation, help patients complete their medical treatment?
- What challenges might hospitals face when dealing with staff and equipment shortages?
Related articles
Protein linked to chemotherapy resistance in ovarian cancer
Scientists found that some ovarian cancer cells survive cisplatin chemotherapy by stabilising their internal scaffold. They identified a protein that can be blocked in laboratory tests to restore the drug's effectiveness and may serve as a biomarker.
Personalized DNA vaccine shows promise against glioblastoma
A phase 1 trial found the personalized DNA vaccine GNOS-PV01 is safe and shows early signs of activity against glioblastoma. The small study at Siteman Cancer Center and WashU Medicine reported immune responses and encouraging clinical outcomes.
